Show simple item record

dc.contributor.authorLu, Sheldon
dc.date.accessioned2014-06-04T02:39:13Z
dc.date.available2014-06-04T02:39:13Z
dc.date.issued6/4/2014en
dc.identifier.urihttp://hdl.handle.net/10675.2/318843
dc.descriptionThe file you are attempting to access is currently restricted to Augusta University. Please log in with your NetID if off campus.en
dc.description.abstractThe discovery and subsequent characterization of endogenous signaling peptides known as bone morphogenetic proteins (BMPs) capable of inducing de novo bone formation in postfetal life represents a critical advancement in the understanding of tissue morphogenesis and has become an incentive to develop additional growth factor based tissue engineering strategies (Wozney & Seeherman 2004). Because BMPs act locally, a suitable carrier system must be used to ensure effective presentation of an adequate dose to a target site (Mont et al. 2004). A number of candidate biomaterials have thus been tested as potential carrier technologies (Huang et al. 2008). Currently, recombinant human BMP-2 (rhBMP-2) coupled with an absorbable collagen sponge (ACS) manufactured from bovine Achilles tendon Type 1 collagen is the only FDA approved device for orthopedic and craniofacial indications. Although the rhBMP-2/ACS construct has demonstrated clinical efficacy for indications including spine fusion, long bone fracture healing, sinus and alveolar augmentation, the ACS’s inability to resist tissue compression limits its use for onlay indications (Wikesjö et al. 2007).
dc.language.isoenen
dc.rightsCopyright protected. Unauthorized reproduction or use beyond the exceptions granted by the Fair Use clause of U.S. Copyright law may violate federal law.en_US
dc.subjectBMPsen
dc.subjectPostfetalen
dc.subjectrecombinant human BMP-2en
dc.subjectabsorbable collagen spongeen
dc.titleEvaluation of a Novel Compression Resistant Matrix for Recombinant Human Bone Morphogenetic Protein-2 (RHBMO-2) for Onlay Graft Indicationsen
dc.typeThesisen
dc.contributor.departmentDepartment of Oral Biologyen
dc.description.advisorWikesjo, Ulfen
dc.description.majorMasters of Science in Oral Biologyen
dc.description.committeeBisch, Frederick; Dixon, Douglas; Lewis, Jillen
html.description.abstractThe discovery and subsequent characterization of endogenous signaling peptides known as bone morphogenetic proteins (BMPs) capable of inducing de novo bone formation in postfetal life represents a critical advancement in the understanding of tissue morphogenesis and has become an incentive to develop additional growth factor based tissue engineering strategies (Wozney & Seeherman 2004). Because BMPs act locally, a suitable carrier system must be used to ensure effective presentation of an adequate dose to a target site (Mont et al. 2004). A number of candidate biomaterials have thus been tested as potential carrier technologies (Huang et al. 2008). Currently, recombinant human BMP-2 (rhBMP-2) coupled with an absorbable collagen sponge (ACS) manufactured from bovine Achilles tendon Type 1 collagen is the only FDA approved device for orthopedic and craniofacial indications. Although the rhBMP-2/ACS construct has demonstrated clinical efficacy for indications including spine fusion, long bone fracture healing, sinus and alveolar augmentation, the ACS’s inability to resist tissue compression limits its use for onlay indications (Wikesjö et al. 2007).


Files in this item

Thumbnail
Name:
Lu, Sheldon_2014.pdf
Size:
9.037Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record